ESC: All eyes on Pfizer’s tafamidis as European heart confab kicks off
admin 24th August 2018 Uncategorised 0Pfizer’s new data on its drug to treat transthyretin cardiomyopathy will likely steal the spotlight at the European Society of Cardiology meeting, but study results from Johnson & Johnson, Bayer, AstraZeneca and Amgen could also draw interest.
More: ESC: All eyes on Pfizer’s tafamidis as European heart confab kicks off
Source: fierce